Tobam Repligen Corp Transaction History

Tobam

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	SELL	$138.78 - $176.51 $64,532 - $82,077	-465 Reduced 57.69%	341 $54,000
Q2 2023 Jul 31, 2023	BUY	$138.42 - $180.31 $46,370 - $60,403	335 Added 71.13%	806 $114,000
Q1 2023 May 03, 2023	SELL	$154.26 - $198.1 $132,355 - $169,969	-858 Reduced 64.56%	471 $79,000
Q4 2022 Feb 02, 2023	SELL	$162.42 - $220.56 $94,366 - $128,145	-581 Reduced 30.42%	1,329 $225,000
Q3 2022 Nov 02, 2022	SELL	$160.42 - $256.21 $92,722 - $148,089	-578 Reduced 23.23%	1,910 $357,000
Q2 2022 Aug 02, 2022	BUY	$140.68 - $188.02 $313,435 - $418,908	2,228 Added 856.92%	2,488 $404,000
Q1 2022 Apr 25, 2022	BUY	$161.19 - $257.96 $13,539 - $21,668	84 Added 47.73%	260 $49,000
Q4 2020 Feb 03, 2021	BUY	$148.08 - $206.57 $26,062 - $36,356	176 New	176 $34,000

479

54.9M

297K

343K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.15B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

Stay updated on Tobam with notifications on news.